

Attorney's Docket No.: 08191

INITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert G. Urban et al.

Art Unit: 1648

Serial No.: 10/603,062

Examiner: Ali R. Salimi

Filed

: June 24, 2003

Title

IMMUNOGENIC PEPTIDES FROM THE HPV E7 PROTEIN

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), this application relies on the earlier filing date of application serial number 09/759,960, filed on January 12, 2001. Those references listed on the attached PTO-1449 form that were submitted to and/or cited by the Office in the prior application are not provided in this application.

This statement is being filed after a first Office Action on the merits, but before receipt of a final Office Action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of §1.17(p) is enclosed.

03/21/2006 MBIZUNES 00000054 10603062

01 FC:1806

180.00 OP

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 16, 2006

Date of Deposit

Carol Tyrrell

Typed or Printed Name of Person Signing Certificate

Applicant: Robert G. Urban et al.

Serial No.: 10/603,062 Filed: June 24, 2003

Page : 2 of 2

3

Please apply any other charges or credits to Deposit Account No. 06 1050, referencing Attorney Docket No. 08191-008004.

Respectfully submitted,

Attorney's Docket No.: 08191-004004

Date: March 16 1206

Jack Brennan Reg. No. 47,443

Fish & Richardson P.C. Citigroup Center 52nd Floor 153 East 53rd Street New York, New York 10022-4611

Telephone: (212) 765-5070 Facsimile: (212) 258-2291

30272582.doc

(Modified)

S.Department of Commerce Septent and Trademark Office

Attorney's Docket No. 08191-004004

Application No.

Substitute Form PTO 149 U.S. Department of (Modified)

Information Discourse Statement

Applicant Robert G. Urban et al. 10/603,062

by Applicant (Use several sheets if necessary)

Group Art Unit 1648

(37 CFR §1.98(b))

Filing Date June 24, 2003

	·	T 5 .		nt Documents	1		T = 0
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,741,872	05/03/1998	DeLuca et al.		,	
	AB	4,777,239	10/11/1988	Schoolnik et al.			
	AC	5,075,109	12/24/1991	Tice et al.			
	AD	5,413,797	05/09/1995	Khan et al.			
	AE	5,547,846	08/20/1996	Bartsch et al.			
-	AF	5,580,859	12/03/1996	Felgner et al.			
	AG	5,589,466	12/31/1996	Felgner et al.			
	AH	5,593,972	01/14/1997	Weiner et al.			
	AI	5,643,605	07/01/1997	Cleland et al.			
	AJ	5,648,459	07/15/1997	Cole et al.			
	AK	5,656,297	08/12/1997	Bernstein et al.			
	AL	5,679,647	10/21/1997	Carson et al.			
	AM	5,695,770	12/09/1997	Raychaudhuri et al.			
	AN	5,703,055	12/30/1997	Felgner et al.			
.,	AO	5,705,151	01/06/1998	Dow et al.			
	AP	5,709,860	01/20/1998	Raychaudhuri et al.			
	AQ	5,733,548	03/31/1998	Restifo et al.			
	AR	5,783,567	07/21/1998	Hedley et al.			
	AS	5,846,540	12/08/1998	Restifo et al.			
	AT	6,007,806	12/28/1999	Lathe et al.			
	AU	6,013,258	1/11/2000	Urban et al.			
	AV	6,037,135	3/14/2000	Kubo et al.			
	AW	6,183,746	02/06/2001	Urban et al.			
	AX	6,582,704	06/24/2003	Urban et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	l ID	Number	Date	Patent Office	Class	Subclass	Yes	Nο

Exam	iner	Signature	

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1

Department of Commerce Patent and Trademark Office

Attorney's Docket No. Application No. 08191-004004 10/603,062

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Robert G. Urban et al.

Applicant

Filing Date

(37 CFR §1.98(b))

Group Art Unit June 24, 2003 1648

	Foreig	n Patent Doo	uments or P	ublished Foreign	Patent A	Application	าร	
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	AY	60-147368	07/04/1985	Japan				
	AZ	WO 92/10513	06/25/1992	PCT				
	AAA	WO 93/22338	11/11/1993	PCT				
	ABB	WO 94/03205	2/17/1994	PCT				
	ACC	WO 94/04171	03/03/1994	PCT				
<u> </u>	ADD	WO 94/04557	03/03/1994	PCT				
	AEE	WO 94/20127	09/15/1994	PCT				
	AFF	WO 94/21680	09/29/1994	PCT				
	AGG	WO 94/23738	10/27/1994	PCT				
	АНН	WO 95/24929	11/21/1995	PCT		-		
	AII	WO 96/00583	01/11/1996	PCT				
	AJJ	WO 97/17063	05/15/1997	PCT				
	AKK	WO 97/33602	09/18/1997	PCT				
	ALL	WO 97/34617	9/25/1997	PCT				
	AMM	WO 97/34621	9/25/1997	PCT		,		
	ANN	WO 97/42940	11/20/1997	PCT		· · · · · · · · · · · · · · · · · · ·		
	AOO	WO 98/31398	07/23/1998	PCT				
	APP	WO 99/45954	9/16/1999	PCT				

(Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
	AQQ	Collins et al., "processing of Exogenous Lipsome-Encapsulat4ed Antigens In Vivo Generates Class I MHC-restricted T Cell Responses," THE JOURNAL OF IMMUNOLOGY, 148:3336-3341, No. 11, June 1, 1992			
	ARR	Elliott et al., "Processing of Major Histocompatibility Class I-restricted Antigens in the Endoplasmic Reticulum," THE JOURNAL OF EXPERIMENTAL MEDICINE, 181:1481-1491, April 1995			
	ASS	Donnelly et al., "immunization with DNA," JOURNAL OF IMMUNOLOGICAL METHODS, 176:145-152, No. 2, 1994			
	ATT	Feltkamp et al., "Vaccination with cytotoxic T Lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells," EUROPEAN JOURNAL OF IMMUNOLOGY, 23:2242-2249, 1993			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant	t in conformance and not considered. Include copy of this form with

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-004004	Application No. 10/603,062	
Information Discl	losure Statement plicant	Applicant Robert G. Urban et al.		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date June 24, 2003	Group Art Unit 1648	

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	AUU	Fries et al., "Liposomal Malaria Vaccine in Humans: A Safe and Potent adjuvant Strategy," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 89:358-362, January 1992
	AVV	Fynan et al., "DNA Vaccines: Protective Immunizations by Parenteral, Mucosal, and Gene-Gun Inoculations," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 90:11478-11482, 1993
	AWW	Gao et al., "Tumor-Associated E6 Protein of Human Papillomavirus Type 16 Contains an Unusual H-2K ^b -Restricted Cytotoxic T Cell Epitope," THE JOURNAL OF IMMUNOLOGY, 155:5519-5526, 1995
	AXX	Hurtenbach et al., "Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice by Treatment with a Class II Major Histocompatibility Complex-blocking Peptide," THE JOURNAL OF EXPERIMENTAL MEDICINE, 177:1499-1504, 1993
	AYY	Jochmus et al., "Specificity of human cytotoxic T Lymphocytes induced by a human papillomavirus type 16 E7-derived peptide," THE JOURNAL OF GENERAL VIROLOGY, 78:1689-1695, 1997
	AZZ	Kadish et al., "Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific," THE JOURNAL OF GENERAL VIOLOGY, 75:2277-2284, 1994
	AAAA	Kadish et al., "Lymphoproliferative Responses to Human Papillomavirus (HPV) Type 16 Proteins E6 and E7: Outcome of HPV Infection and Associated Neoplasia," JOURNAL OF THE NATIONAL CANCER INSTITUTE, 89:1285, 1997
	ABBB	Kast et al., "Human Leukocyte Antien-A2.1 Restricted Candidate Cytotoxic T Lymphocyte Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins Identified by Using the Processing-Defective Human Cell Line T2," THE JOURNAL OF IMMUNOTHERAPY, 14:115-120, 1993
	ACCC	Kast et al., "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins," THE JOURNAL OF IMMUNOLOGY, 152:3904-3912, 1994
	ADDD	Lin et al., "Treatment of Established Tumors with a Novel Vaccine that Enhances Major Histocompatibility Class II Presentation of Tumor Antigen," CANCER RESEARCH, 56:21-26, 1996
	AEEE	Loftus et al., "Analysis of MHC-specific peptide motifs: applications in immunotherapy," Advances in Experimental Medicine and Biology; Immunobiology of proteins and peptides VIII. Manipulation or modulation of the immune response, 1995, pp. 201-210.
	AFFF	Madden et al., "The Antigenic Identity of Peptide-MHC Complexes: A Comparison of the conformations of Five Viral Peptides Presented by HLA-A2," CELL, 75:693-708, November 19, 1993
	AGGG	Mowat et al., "ISCOMS - A Novel Strategy for Mucosal Immunization?", IMMUNOLOGY TODAY, 12:383-385, 1991
	АННН	Nabel et al., "Transduction of a Foreign Histocompatibility Gene into the Arterial Wall Induces Vasculitis," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 89:5157-5161, No. 11, June 1992
	AIII	Osband et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy," IMMUNOLOGY TODAY, 11:193-195, 1990
	AJJJ	Reddy et al., "In Vivo Cytotoxic T Lymphocyte Induction with Soluble Proteins Administered in Liposomes," THE JOURNAL OF IMMUNOLOGY, 148:1585-1589, No. 5, March 1992

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if next communication to applicant.	of in conformance and not considered. Include copy of this form with

,	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-004004	Application No. 10/603,062
		closure Statement	Applicant Robert G. Urban et a	ıl.
	(Use several sheets if necessary) (37 CER \$1.98(b))		Filing Date June 24, 2003	Group Art Unit 1648

(Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
		Ressing et al., "Occasional Memory Cytotoxic T-Cell Responses of Patients with Human
	AKKK	Papillomavirus Type 16-positive Cervical Lesions against a Human Leukocyte Antigen-A 0201-
		restricted E7-encoded Epitope," CANCER RESEARCH, 56:582-588, February 1, 1996
		Ressing et al., "human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7
	ALLL	Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A 0201 Binding
		Peptides," THE JOURNAL OF IMMUNOLOGY, 154:5934-5943, June 1, 1995
	AMMM	Shrine et al., "Pangaea Aims Naturally Processed Peptides at First viral Target: Human Papilloma
	Aiviiviivi	Virus," BIOWORLD TODAY, THE BIOTECHNOLOGY NEWSPAPER, 7:1-2, May 15, 1996
	ANNN	Stellar et al., "Human Papillomavirus Immunology and Vaccine Prospects," JOURNAL OF THE
	7111111	NATIONAL CANCER INSTITUTE MONOGRAPHS, No. 21, 1996, pp. 145-148
	A000	Takahashi et al., "Induction of CD8 Cytotoxic T Cells by Immunization with Purified HIV-1
	7.000	Envelope Protein in ISCOMs," NATURE, 344:873-875, April 1990
		Tarpey et al., "Human Cytotoxic T Lymphocytes Stimulated by Endogenously processed human
	APPP	papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif,"
		IMMUNOLOGY, 81:222-227, 1994
		Tsukui et al., "Interleukin 2 Production in vitro by Peripheral Lymphocytes in response to Human
	AQQQ	Papillomavirus-derived peptides: Correlation with Cervical Pathology," CANCER RESEARCH,
		56:3855-4085, 1996
	ARRR	Urban et al., "A subset of HLA-B27 Molecules contains peptides much longer than nonamers,"
		PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 91:1534-1538, February 1994
	ASSS	Vitiello et al., "Development of a Lipopeptide Based Therapeutic Vaccine to Treat chronic HBV
		Infection, THE JOURNAL O FCLINICAL INVESTIGATION, 95:341-349, January 1995
	* 3222	Vitiello et al., "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte
	ATTT	Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility
	ļ	Complex," J. EXP. MED., 173:1007-1015, April 1991
	A T 117 17 7	Zhu et al., "Both Immunization with Protein and Recombinant Vaccinia Virus Can Stimulate CTL
	AUUU	Specific for the E7 Protein of Human Papilloma Virus 16 in H-2 ^d Mice," SCANDINAVIAN
	<u> </u>	JOURNAL OF IMMUNOLOGY, 42:557-563, 1995

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with